SITC 2022 | How can high endothelial venules move CD8+ T cells into the tumor during IO?
Lucas Blanchard
• 21 Nov 2022
Lucas Blanchard, MS, CNRS-IPBS, Toulouse, France, discusses the role of high endothelial venules (HEVs) mediate lymphocyte trafficking during anti-PD-1 and anti-CTLA-4 immunotherapy. HEVs are a specialized form of blood vessels and lymph node HEVs have found to induce generation of stem-like CD8+ T cells in tumor-draining lymph nodes, whereas tumor-associated HEVs facilitate entry of peripheral stem-like CD8+ T cells into the tumor. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
